SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: John Arnett who wrote (537)12/29/1997 3:14:00 PM
From: james  Read Replies (1) | Respond to of 975
 
JA, p3 trial failures are usually due to:

(1). Side-effects are too seriouse
(2). The drugs have no efficacy
(3). Slopy p3 trial management, & thus inconclusive data.

My personal impression of the blsi's Therafectin p3 failure is not due to (1) & (2), but (3), which could be WRONG. If it goes ahead for filing NDA, I can't see any negative.

2nd-3rd p3 trials happens from time to time. If other pharmas pick it up, that is definitely POSITIVE. If blsi re-trial on it own, I will be VERY VERY CAUTIOUSE.

As to delisting, I have no idea.

Happy 98